PPIDT00228
Drug Information
| Name | Pasireotide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06663 |
| Type | small molecule |
| Indication | For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
0.3 mg/1mL
|
| Injection | Subcutaneous |
0.6 mg/1mL
|
| Injection | Subcutaneous |
0.9 mg/1mL
|
| Injection, powder, for suspension | Intramuscular |
10 mg
|
| Injection, powder, for suspension | Intramuscular |
30 mg
|
| Injection, powder, for suspension | Intramuscular; Parenteral |
10 MG
|
| Injection, powder, for suspension | Intramuscular; Parenteral |
20 MG
|
| Injection, powder, for suspension | Intramuscular; Parenteral |
30 MG
|
| Injection, powder, for suspension | Intramuscular; Parenteral |
40 MG
|
| Injection, powder, for suspension | Intramuscular; Parenteral |
60 MG
|
| Solution | Subcutaneous |
0.3 mg / mL
|
| Solution | Subcutaneous |
0.6 mg / mL
|
| Solution | Subcutaneous |
0.9 mg / mL
|
| Solution | — |
0.3 mg/1ml
|
| Solution | — |
0.6 mg/1ml
|
| Solution | — |
0.9 mg/1ml
|
| Injection, powder, for suspension | Intramuscular |
6000000 mg
|
| Injection | Subcutaneous |
|
| Injection, solution | Subcutaneous |
0.3 mg/1ml
|
| Injection | Subcutaneous |
0.375 mg/ml
|
| Solution | Oral |
0.3 mg/1ml
|
| Injection, solution | Subcutaneous |
0.6 mg/1ml
|
| Solution | Oral |
0.6 mg/1ml
|
| Injection, solution | Subcutaneous |
0.9 mg/1ml
|
| Solution | Oral |
0.9 mg/1ml
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
10 mg
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
20 mg
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
30 mg
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
40 mg
|
| Injection, powder, for suspension, extended release; kit | Intramuscular |
60 mg
|
| Injection, powder, for suspension; kit | Intramuscular |
10 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
15 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
20 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
30 mg/1mL
|
| Injection, powder, for suspension; kit | Intramuscular |
5 mg/1mL
|
| Kit | Intramuscular |
5 mg/1mL
|
| Injection, powder, for suspension | — |
10 mg/1vial
|
| Injection, powder, for suspension | — |
20 mg/1vial
|
| Injection, powder, for suspension | — |
30 mg/1vial
|
| Injection, powder, for suspension | — |
40 mg/1vial
|
| Powder, for solution | Oral |
20 mg
|
| Powder, for solution | Oral |
40 mg
|
| Powder, for solution | Oral |
60 mg
|
| Injection, powder, for suspension | Intramuscular |
20 mg
|
| Injection, powder, for suspension | Intramuscular |
40 mg
|
| Injection, powder, for suspension | Intramuscular |
60 mg
|
| Injection, powder, for suspension | — |
60 mg/1vial
|
| Injection, solution | Subcutaneous |
0.3 mg
|
| Injection, solution | Subcutaneous |
0.6 mg
|
| Injection, solution | Subcutaneous |
0.9 mg
|
| Solution | Subcutaneous |
0.3 mg
|
| Solution | Subcutaneous |
0.6 mg
|
| Solution | Subcutaneous |
0.9 mg
|
| Injection, powder, for suspension | Intramuscular |
2742000 mg
|
| Injection, powder, for suspension | Intramuscular |
4000000 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P32745 | SSTR3 | Somatostatin receptor type 3 | Homo sapiens | inhibitor | Link |
| target | P30872 | SSTR1 | Somatostatin receptor type 1 | Homo sapiens | inhibitor | Link |
| target | P30874 | SSTR2 | Somatostatin receptor type 2 | Homo sapiens | inhibitor | Link |
| target | P35346 | SSTR5 | Somatostatin receptor type 5 | Homo sapiens | inhibitor | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | inhibitor | Link |